Literature DB >> 10507593

Cytokine expression in severe pneumonia: a bronchoalveolar lavage study.

C Montón1, A Torres, M El-Ebiary, X Filella, A Xaubet, J P de la Bellacasa.   

Abstract

OBJECTIVE: To assess the cytokine expression (tumor necrosis factor-alpha [TNF-alpha], interleukin [IL]-1beta, and IL-6) in severe pneumonia, both locally (in the lungs) and systemically (in blood).
DESIGN: Prospective sequential study with bronchoalveolar lavage (BAL) and blood sampling.
SETTING: Six-bed respiratory intensive care unit of a 1,000-bed teaching hospital. PATIENTS: Thirty mechanically ventilated patients (>48 hrs) were allocated to either the pneumonia group (n = 20) or a control group (n = 10).
INTERVENTIONS: Protected specimen brush and BAL samples for quantitative cultures, and serum and BAL fluid TNF-alpha, IL-1beta, and IL-6 levels were measured on days 1, 3, and 7. In the control group, the procedure was done on day 1 only.
MEASUREMENTS AND MAIN RESULTS: Serum TNF-alpha levels were significantly higher in patients with pneumonia compared with controls (35 +/- 4 vs. 17 +/- 3 pg/mL, respectively, p = .001). IL-6 levels in serum and BAL fluid were higher in pneumonia than in control patients (serum, 837 +/- 260 vs. 94 +/- 35 pg/mL, respectively, p = .017; BAL fluid, 1176 +/- 468 vs. 234 +/- 83 pg/mL, respectively, p = .05). On days 1, 3, and 7 in patients with pneumonia, IL-1beta levels turned out to be higher in BAL fluid than in serum (71 +/- 17 vs. 2 +/-1 pg/mL on day 1; 49 +/- 8 vs. 6 +/- 2 pg/mL on day 3; and 47 +/- 16 vs. 3 +/- 2 pg/mL on day 7 for BAL fluid and serum, respectively, p < .05). No significant correlation between BAL fluid cytokine levels and lung bacterial burden was shown in presence of antibiotic treatment. Although no clear relationship was found between BAL fluid and serum cytokines and mortality, there was a trend toward higher serum IL-6 levels in nonsurvivors (1209 +/- 433 pg/mL) with pneumonia compared with survivors (464 +/- 260 pg/mL). In addition, serum TNF-alpha and IL-6 correlated with multiple organ failure score (r2 = .36, p = .004 for both) and with lung injury score (r2 = .30, p = .01, and r2 = .22, p = .03, for TNF-alpha and IL-6, respectively).
CONCLUSIONS: The present study describes the lung and systemic inflammatory response in severe pneumonia. The lung cytokine expression seems to be independent from the lung bacterial burden in the presence of antibiotic treatment. Because of the limited sample size, we did not find a clear relationship between serum and BAL fluid cytokine levels and outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507593     DOI: 10.1097/00003246-199909000-00008

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  32 in total

Review 1.  Homeostasis and its disruption in the lung microbiome.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

2.  Corticosteroids in the treatment of severe community-acquired pneumonia.

Authors:  Tasha D Ramsey; Sean K Gorman
Journal:  Curr Infect Dis Rep       Date:  2014-05       Impact factor: 3.725

3.  Hospital-acquired pneumonia is an independent predictor of poor global outcome in severe traumatic brain injury up to 5 years after discharge.

Authors:  Matthew Ryan Kesinger; Raj G Kumar; Amy K Wagner; Juan Carlos Puyana; Andrew P Peitzman; Timothy R Billiar; Jason L Sperry
Journal:  J Trauma Acute Care Surg       Date:  2015-02       Impact factor: 3.313

4.  Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

Authors:  S Padrones; C Garcia-Vidal; S Fernández-Serrano; A Fernández; C Masuet; J Carratalà; M Coromines; C Ardanuy; F Gudiol; F Manresa; J Dorca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-22       Impact factor: 3.267

5.  Development of a novel preclinical model of pneumococcal pneumonia in nonhuman primates.

Authors:  Bryan D Kraft; Claude A Piantadosi; Ashlee M Benjamin; Joseph E Lucas; Aimee K Zaas; Marisol Betancourt-Quiroz; Christopher W Woods; Alan L Chang; Victor L Roggli; Craig D Marshall; Geoffrey S Ginsburg; Karen Welty-Wolf
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

6.  Early-Onset Ventilator-Associated Pneumonia in Patients with Severe Traumatic Brain Injury: Incidence, Risk Factors, and Consequences in Cerebral Oxygenation and Outcome.

Authors:  Pierre Esnault; Cédric Nguyen; Julien Bordes; Erwan D'Aranda; Ambroise Montcriol; Claire Contargyris; Jean Cotte; Philippe Goutorbe; Christophe Joubert; Arnaud Dagain; Henry Boret; Eric Meaudre
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

7.  Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections.

Authors:  Natividad Benito; Asunción Moreno; Xavier Filella; José M Miró; Julià González; Tomás Pumarola; María Eugenia Valls; Montserrat Luna; Felipe García; Ana Rañó; Antoni Torres; José M Gatell
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

8.  Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia.

Authors:  Silvia Fernández-Serrano; Jordi Dorca; Mercè Coromines; Jordi Carratalà; Francesc Gudiol; Frederic Manresa
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

9.  Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Authors:  Esther Calbo; Montserrat Alsina; Mónica Rodríguez-Carballeira; Josep Lite; Javier Garau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

10.  Serum and pleural fluid procalcitonin in predicting bacterial infection in patients with parapneumonic effusion.

Authors:  Yang-Ching Ko; Wen-Pin Wu; Chi-Sen Hsu; Mong-Ping Dai; Chien-Chih Ou; Chih-Hsiung Kao
Journal:  J Korean Med Sci       Date:  2009-06-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.